Sartorius Stedim Biotech SA banner

Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 164.4 EUR -4.06% Market Closed
Market Cap: €16B

Sartorius Stedim Biotech SA
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sartorius Stedim Biotech SA
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Sartorius Stedim Biotech SA
PAR:DIM
Non-Reccuring Items
-€15.2m
CAGR 3-Years
31%
CAGR 5-Years
14%
CAGR 10-Years
-7%
Eurofins-Cerep SA
PAR:ALECR
Non-Reccuring Items
€300k
CAGR 3-Years
N/A
CAGR 5-Years
30%
CAGR 10-Years
-2%
No Stocks Found

Sartorius Stedim Biotech SA
Glance View

Sartorius Stedim Biotech SA has been weaving the intricate threads of biotechnology innovation into a fabric of global influence and success. Established as a pivotal player in the biopharmaceutical industry, Sartorius Stedim Biotech has carved out a niche by offering sophisticated products and solutions that cater to the unique needs of biopharmaceutical manufacturers. The company’s portfolio is a testament to the fusion of scientific ingenuity and relentless pursuit of quality. Spanning filtration and purification solutions, fermentation equipment, and fluid management systems, their offerings ensure that complex biological drugs, including vaccines and monoclonal antibodies, are produced efficiently and safely. Sartorius Stedim Biotech’s endeavor is not just about supplying equipment; it’s about providing integrated solutions that optimize the entire production process, ensuring consistency, scalability, and compliance in industries bound by strict regulatory oversight. The company generated revenue through its comprehensive range of products and services that address every step of the biomanufacturing process. Their business model hinges on fostering long-term relationships with clients by offering tailored solutions that enhance productivity and reduce time-to-market for new therapies. Beyond direct sales of high-value equipment, Sartorius Stedim Biotech also capitalizes on recurring revenue streams generated from consumables and maintenance services essential for the ongoing operation of their systems. By continuously innovating and expanding its product lines, the company stays at the forefront of technological advancements, enabling clients to tackle the ever-evolving challenges of bioproduction. As the global biopharmaceutical industry surges forward, driven by increasing demand for biologics, Sartorius Stedim Biotech remains poised to maintain its role as an indispensable ally to firms dedicated to transforming the health landscape through revolutionary therapies.

DIM Intrinsic Value
136.9 EUR
Overvaluation 17%
Intrinsic Value
Price

See Also

What is Sartorius Stedim Biotech SA's Non-Reccuring Items?
Non-Reccuring Items
-15.2m EUR

Based on the financial report for Dec 31, 2025, Sartorius Stedim Biotech SA's Non-Reccuring Items amounts to -15.2m EUR.

What is Sartorius Stedim Biotech SA's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 10Y
-7%

Over the last year, the Non-Reccuring Items growth was 65%. The average annual Non-Reccuring Items growth rates for Sartorius Stedim Biotech SA have been 31% over the past three years , 14% over the past five years , and -7% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett